Ursula Trafojer
YOU?
Author Swipe
View article: Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial
Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial Open
Within this study population, we found no evidence that meropenem was superior to SOC in terms of success at TOC, short term hearing disturbances, safety or mortality were similar in both treatment arms but the study was underpowered to de…
View article: Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial
Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial Open
Background The early use of broad-spectrum antibiotics remains the cornerstone for the treatment of neonatal late onset sepsis (LOS). However, which antibiotics should be used is still debatable, as relevant studies were conducted more tha…
View article: Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies
Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies Open
Simulations showed that longer infusions increase plasma PTA but decrease CSF PTA. CSF penetration is worsened with long infusions so increasing dose frequency to achieve therapeutic targets should be considered.